ArticleInternational journal of clinical and experimental pathology2017
Prognostic significance of CD4 and interleukin-22 expression in pancreatic cancer.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- The role of IL-22 in cancer.Medical oncology (Northwood, London, England) · 2024Review
- T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer.Cancers · 2022Article
- The Assessment of IL-21 and IL-22 at the mRNA Level in Tumor Tissue and Protein Concentration in Serum and Peritoneal Fluid in Patients with Ovarian Cancer.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most aggressive cancers. Interleukin-22 (IL-22) is a member of IL-10 cytokine family and primarily produced by Th17 cells which were differentiated from CD4 T cells. CD4 T cells play a central role in regulating the immune response and resisting cancer cells. However, the function of CD4 T cells and Interleukin-22 (IL-22) in the microenvironment of pancreatic cancer remains largely unknown. In the present study, we investigated expression of the IL-22 in tumor cells, CD4 expression in microenvironment of pancreatic cancer and assessed their effects on pathological characteristics and prognosis of pancreatic cancer. To analyze prognostic factors of pancreatic cancer, Kaplan-Meier survival and Cox proportional-hazards regression were applied. Expression of CD4 in pancreatic cancer was associated with pTNM stage (P=0.005). Expression of IL-22 in pancreatic cancer was related not only to pTNM stage (P=0.011) but also to lymph node involvement (P=0.016). Univariate analysis demonstrated that the main prognostic factors of pancreatic cancer are pathological differentiation, expression of low CD4, expression of high IL-22 and the combination of low CD4 expression and high IL-22 expression in pancreatic cancer tissues. Moreover, multivariate analysis clearly showed that pathological differentiation, and the combination of low CD4 expression and high IL-22 expression in pancreatic cancer tissues were independent prognostic factors for overall survival in pancreatic cancer. the present study indicated that CD4 and IL-22 might be used as independent prognostic markers and molecular targets for pancreatic cancer.
Indexed as
Identifiers
31966872PMC6965920W3027282886What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.